Document:

EX-10.4

 Exhibit 10.4 

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT 

THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, effective as of August 11, 2021 (as it may from time to time be amended, this
“Agreement”), is entered into by and between AfterNext HealthTech Acquisition Corp., a Cayman Islands exempted company (the “Company”), and AfterNext HealthTech Sponsor, Series LLC, a Delaware series limited
liability company (the “Purchaser”). 
 WHEREAS: 

The Company intends to consummate an initial public offering of the Company’s units (the “Public Offering”), each unit consisting of one
Class A ordinary share of the Company, par value $0.0001 per share (each, a “Share”), and one-third of one redeemable warrant as set forth in the Company’s registration statement on
Form S-1, filed with the Securities and Exchange Commission (the “SEC”), File Number 333-257815 (the “Registration Statement”), under
the Securities Act of 1933, as amended (the “Securities Act”) 
 Each whole warrant entitles the holder to purchase one Share at an
exercise price of $11.50 per Share; and 
 The Purchaser has agreed to purchase an aggregate of 4,666,667 warrants (or up to 5,166,667 warrants if the
over-allotment option in connection with the Public Offering is exercised in full) (the “Private Placement Warrants”), each Private Placement Warrant entitling the holder to purchase one Share at an exercise price of $11.50 per
Share. 
 NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows: 

AGREEMENT 
 Section 1.
Authorization, Purchase and Sale; Terms of the Private Placement Warrants. 
 A. Authorization of the Private Placement Warrants. The Company has
duly authorized the issuance and sale of the Private Placement Warrants to the Purchaser. 
 B. Purchase and Sale of the Private Placement Warrants.

 (i) On the date of the consummation of the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company
(the “Initial Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, 4,666,667 Private Placement Warrants at a price of $1.50 per warrant for an aggregate purchase price
of $7,000,000 (the “Purchase Price”), which shall be paid by wire transfer of immediately available funds to the Company in accordance with the Company’s wiring instructions. On the Initial Closing Date, upon the payment by the
Purchaser of the Purchase Price by wire transfer of immediately available funds to the Company, the Company, at its option, shall deliver a certificate evidencing the Private Placement Warrants purchase on such date duly registered in the
Purchaser’s name to the Purchaser or effect such delivery in book-entry form. 
 (ii) On the date of the consummation of the closing of the
over-allotment option in connection with the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “Over-allotment Closing Date”, and each Over-allotment Closing Date (if
any) and the Initial Closing Date being sometimes referred to herein as “Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, up to 500,000 Private Placement Warrants
at a price of $1.50 per warrant for an aggregate purchase price of up to $750,000 (if the over-allotment option in connection with the Public Offering is exercised in full) (the “Over-allotment Purchase Price”), which shall be paid
by wire transfer of immediately available funds to the Company in accordance with the Company’s wiring instructions. On the Over-allotment Closing Date, upon the payment by the Purchaser of the Over-allotment Purchase Price by wire transfer of
immediately available funds to the Company, the Company shall, at its option, deliver a certificate evidencing the Private Placement Warrants purchased on such date duly registered in the Purchaser’s name to the Purchaser or effect such
delivery in book-entry form. 

 C. Terms of the Private Placement Warrants. 

(i) Each Private Placement Warrant shall have the terms set forth in a Warrant Agreement to be entered into by the Company and a warrant agent, in connection
with the Public Offering (the “Warrant Agreement”). 
 (ii) At the time of the closing of the Public Offering, the Company and the
Purchaser shall enter into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Private Placement Warrants and
the Shares underlying the Private Placement Warrants. 
 Section 2. Representations and Warranties of the Company. As a
material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants, the Company hereby represents and warrants to the Purchaser (which representations and warranties shall survive each Closing Date) that:

 A. Organization and Corporate Power. The Company is an exempted company duly incorporated, validly existing and in good standing under the laws of
the Cayman Islands and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The
Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement. 

B. Authorization; No Breach. 
 (i) The execution,
delivery and performance of this Agreement and the Private Placement Warrants have been duly authorized by the Company as of the Closing Date. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with
its terms. Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Private Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with
their terms as of each Closing Date. 
 (ii) The execution and delivery by the Company of this Agreement and the Private Placement Warrants, the issuance
and sale of the Private Placement Warrants, the issuance of the Shares upon exercise of the Private Placement Warrants and the fulfillment, of and compliance with, the respective terms hereof and thereof by the Company, do not and will not as of the
Closing Date (a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s
share capital or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or
agency pursuant to the amended and restated memorandum and articles of association of the Company (in effect on the date hereof or as may be amended prior to completion of the contemplated Public Offering), or any material law, statute, rule or
regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof under federal or state securities laws. 

C. Title to Securities. Upon issuance in accordance with, and payment pursuant to, and registration in the register of members of the Company, the
terms hereof and the Warrant Agreement, the Shares issuable upon exercise of the Private Placement Warrants will be duly and validly issued, fully paid and nonassessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof
and the Warrant Agreement, the Purchaser will have good title to the Private Placement Warrants purchased by it and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances of any
kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the
actions of the Purchaser. 

 D. Governmental Consents. No permit, consent, approval or authorization of, or declaration to or
filing with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other transactions contemplated hereby. 

Section 3. Representations and Warranties of the Purchaser. As a material inducement to the Company to enter into this
Agreement and issue and sell the Private Placement Warrants to the Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive each Closing Date) that: 

A. Organization and Requisite Authority. The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated
by this Agreement. 
 B. Authorization; No Breach. 

(i) This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law). 

(ii) The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and
shall not as of the Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject. 

C. Investment Representations. 
 (i) The Purchaser is
acquiring the Private Placement Warrants and, upon exercise of the Private Placement Warrants, the Shares issuable upon such exercise (collectively, the “Securities”), for the Purchaser’s own account, for investment purposes
only and not with a view towards, or for resale in connection with, any public sale or distribution thereof. 
 (ii) The Purchaser is an “accredited
investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act. 
 (iii) The Purchaser understands that the Securities
are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the
Purchaser’s compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities. 

(iv) The Purchaser did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule
502(c) under the Securities Act. 
 (v) The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company
and materials relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors of the Company. The Purchaser
understands that its investment in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition of the
Securities. 
 (vi) The Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or
made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 

 (vii) The Purchaser understands that: (a) the Securities have not been and are not being registered
under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; and (b) except as
specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder. 
 (viii) The Purchaser has such knowledge and experience in financial and business matters, knowledge of the high degree of
risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment in
the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies and will have no current or anticipated future needs for liquidity
which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investments in the Securities. 

Section 4. Conditions of the Purchaser’s Obligations. The obligations of the Purchaser to purchase and pay for the Private
Placement Warrants are subject to the fulfillment, on or before each Closing Date, of each of the following conditions: 
 A. Representations and
Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of the Closing Date as though then made. 

B. Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before such Closing Date. 
 C. No Injunction. No litigation, statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters
contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 
 D. Warrant
Agreement. The Company shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Purchaser. 

Section 5. Conditions of the Company’s Obligations. The obligations of the Company to the Purchaser under this Agreement are
subject to the fulfillment, on or before each Closing Date, of each of the following conditions: 
 A. Representations and Warranties. The
representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of such Closing Date as though then made. 

B. Performance. The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by the Purchaser on or before such Closing Date. 
 C. No Injunction. No litigation, statute, rule,
regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the
matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement. 
 D.
Warrant Agreement. The Company shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Company. 

Section 6. Termination. This Agreement may be terminated at any time after December 31, 2021 upon the election by either the
Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not occur prior to such date. 

 Section 7. Survival of Representations and Warranties. All of the representations
and warranties contained herein shall survive each Closing Date. 
 Section 8. Definitions. Terms used but not otherwise defined
in this Agreement shall have the meaning assigned to such terms in the Registration Statement. 
 Section 9. Miscellaneous. 

A. Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of
any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this
Agreement, other than assignments by the Purchaser to affiliates thereof. 
 B. Severability. Whenever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. 
 C. Counterparts. This Agreement may be executed simultaneously in
two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. 

D. Descriptive Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a
substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of example rather than by limitation. 
 E.
Governing Law. This Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York. 

F. Amendments. This letter agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by
all parties hereto. 
 [Signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date
first set forth above. 
  

			
	COMPANY:
	
	AFTERNEXT HEALTHTECH ACQUISITION CORP.
		
	By:	 	/s/ Art Heidrich
		 	Name: Art Heidrich
		 	Title: Secretary

  

			
	PURCHASER:
	
	AFTERNEXT HEALTHTECH SPONSOR, SERIES LLC
		
	By:	 	/s/ Michael LaGatta
		 	Name:Michael LaGatta
		 	Title: Vice President

  
 [Signature page to
Private Placement Warrants Purchase Agreement]Exhibit
4.2

 

 

4
Nancy Court, Ste 4 / Wappingers Falls, NY 12540

Cent Per Share Private Placement

 

SECURITIES
PURCHASE AGREEMENT (FIXED PRICE EQUITY PRIVATE PLACEMENT

 

Tauriga
Sciences Inc. (OTCQB: TAUG) 4 Nancy Court, Suite 4

 

Wappingers
Falls, NY 12540

Attn:
Seth M. Shaw, Chief Executive Officer.DATE:

 

THIS
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of __, 2021, by and among Tauriga Sciences, Inc., a
Florida corporation (the “Company”), and the Subscriber identified on the signature pages hereto (the “Subscriber”).

 

WHEREAS,
the Company and the Subscriber are executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by the provisions of Section 4(2), Section 4(6) and/or Regulation D (“Regulation D”) as promulgated by the
United States Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the
“1933 Act”).

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Subscriber,
as provided herein, and the Subscriber shall purchase ______ shares (the “Purchased Shares”) of the Company’s
common stock, $.00001 par value (the “Common Stock”) at a per shares price of _______ for an aggregate purchase
price of $ the “Purchase Price”).

 

NOW,
THEREFORE, in consideration of the mutual covenants and other agreements contained in this Agreement, the Company and the Subscriber
hereby agree as follows:

 

1.       Closing.
On the Closing Date (as defined below), the Subscriber shall purchase and the Company shall sell to the Subscriber the Purchased Shares.
The Closing Date shall be the date the Subscriber funds the Purchase Price by wire transfer to the benefit of the Company pursuant to
the instructions set forth on Exhibit A hereto (the “Closing Date”).

 

2.       Subscriber’s
Representations and Warranties. The Subscriber hereby represents and warrants to and agrees with the Company as to such Subscriber
that:

 

    	 

    	 

    

 

(a)       Information
on Company. The Subscriber has received in writing from the Company such public information concerning its operations, financial
condition and other matters as the Subscriber has requested in writing, and considered all factors the Subscriber deems material in deciding
on the advisability of investing in the Securities.

 

 

    	-2-

    	 

    

 

(b)       Information
on Subscriber. The Subscriber is as of the date hereof an “accredited investor”, as such term is defined in Regulation
D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made investments of a speculative
nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with its representatives,
has such knowledge and experience in financial, tax and other business matters as to enable the Subscriber to utilize the information
made available by the Company to evaluate the merits and risks of, and to make an informed investment decision with respect to, the proposed
purchase. The Subscriber acknowledges that an investment in the Securities represents a speculative investment. The Subscriber has the
authority and is duly and legally qualified to purchase and own the Securities. The Subscriber is able to bear the risk of such investment
for an indefinite period and to afford a complete loss of the investment. The information set forth on the signature page hereto regarding
the Subscriber is true and correct.

 

(c)       Compliance
with Securities Act. The Subscriber understands and agrees that the Securities have not been registered under the 1933 Act or any
applicable state securities laws, and are being issued in a transaction that does not require registration under the 1933 Act (based
in part on the accuracy of the representations and warranties of Subscriber contained herein), and that such Securities must be held
indefinitely unless the Securities are subsequently registered for resale under the 1933 Act or any applicable state securities laws
or is exempt from such registration.

 

(d)       Shares
Legend. Upon issuance, the Purchased Shares shall bear the following or similar legend:

 

“THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY STATE SECURITIES LAW. NO TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE SHALL BE VALID OR EFFECTIVE UNLESS SUCH TRANSFER
IS MADE (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES
LAWS, OR (B) PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE STATE OR LOCAL SECURITIES
LAW (INCLUDING WITHOUT LIMITATION THE DELIVERY OF A LEGAL OPINION FROM COUNSEL TO THE TRANSFEROR, REASONABLY SATISFACTORY, IF REQUESTED
BY THE COMPANY).”

 

    	-3-

    	 

    

 

 

    	-4-

    	 

    

 

(e)       Communication
of Offer. The offer to sell the Securities was directly communicated to the Subscriber by the Company. At no time was the Subscriber
presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form of general
advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with such communicated
offer. (f)Authority; Enforceability. This Agreement and the other agreements delivered in connection with this Agreement have
been duly authorized, executed and delivered by the Subscriber and are valid and binding agreements enforceable in accordance with their
terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating
to or affecting creditors’ rights generally and to general principles of equity, Subscriber has full corporate power and authority
necessary to enter into this Agreement and such other agreements and to perform its obligations hereunder and under all other agreements
entered into by the Subscriber relating hereto.

 

(g)       Correctness
of Representations. The Subscriber represents as to such Subscriber that the foregoing representations and warranties are true and
correct as of the date hereof and will be true and correct as of the Closing Date. The foregoing representations and warranties shall
survive the Closing Date for a period of three years.

 

(h)       Survival.
The foregoing representations and warranties of the Subscriber shall survive the Closing Date for a period of two years.

 

3.       Company
Representations and Warranties. The Company represents and warrants to and agrees with the Subscriber that, except as set forth in
the Reports:

 

(a)       Due
Incorporation. The Company and each of its subsidiaries is a corporation duly organized, validly existing and in good standing under
the laws of the respective jurisdictions of their incorporation and have the requisite corporate power to own their properties and to
carry on their business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to
do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such
qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a material adverse effect on
the business, operations or financial condition of the Company.

 

(b)       Outstanding
Stock. All issued and outstanding shares of capital stock of the Company and each of its subsidiaries has been duly authorized and
validly issued and are fully paid and non-assessable.

 

(c)       Authority;
Enforceability. This Agreement and any other agreements delivered in connection herewith (collectively “Transaction
Documents”) have been duly authorized, executed and delivered by the Company and are valid and binding agreements
enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of
equity. The Company has full corporate power and authority necessary to enter into and deliver the Transaction Documents and to
perform its obligations thereunder.

 

    	-5-

    	 

    

 

(d)       The
Securities. The Securities upon issuance:

 

(i)       are,
or will be, free and clear of any security interests, liens, claims or other encumbrances, subject to restrictions upon transfer under
the 1933 Act and any applicable state securities laws; and

 

(ii)       have
been, or will be, duly and validly authorized and as of the Closing Date, the Securities will be duly and validly issued, fully paid
and nonassessable (and if registered pursuant to the 1933 Act, and if resold pursuant to an effective registration statement will be
free trading and unrestricted, provided that the Subscriber complies with the prospectus delivery requirements of the 1933 Act);

 

(e)       Reporting
Company. The Company is a publicly-held company subject to reporting obligations pursuant to Sections 15(d) and 13 of the Securities
Exchange Act of 1934, as amended (the “1934 Act”) and has a class of common stock registered pursuant to Section 12(g)
of the 1934 Act. The Company is Current and is a fully reporting U.S. based public Company which has its securities listed on the OTCQB
Tier of OTC Markets.

 

(f)       No
Market Manipulation. The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might
reasonably be expected to, cause or result in stabilization or manipulation of the price of the Common Stock to facilitate the sale or
resale of the Securities or affect the price at which the Securities may be issued or resold.

 

(g)       Stop
Transfer. The Securities, when issued, will be “restricted” securities, as that term is defined under Rule 144 of the
1933 Act. The Company will not issue any stop transfer order or other order impeding the sale, resale or delivery of any of the Securities,
except as may be required by any applicable federal or state securities laws and unless contemporaneous notice of such instruction is
given to the Subscriber.

 

(h)       No
Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause
the offer of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the 1933
Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Bulletin
Board. The Company or any of its affiliates or subsidiaries will not take any action or steps that would cause the offer of the Securities
to be integrated with other offerings. The Company will not conduct any offering other than the transactions contemplated hereby that
will be integrated with the offer or issuance of the Securities.

 

(i)       No
General Solicitation. Neither the Company, nor any of its affiliates, nor to its knowledge, any person acting on its or their behalf,
has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection
with the offer or sale of the Securities.

 

    	-6-

    	 

    

 

(j)       Dilution.
The Company’s executive officers and directors have studied and fully understand the nature of the Securities being sold hereby
and recognize that they have a potential dilutive effect on the equity holdings of other holders of the Company’s equity or rights
to receive equity of the Company. The board of directors of the Company has concluded, in its good faith business judgment, that such
issuance is in the best interests of the Company.

 

(k)       Going
Concern: There can be no guaranty that the Company will be successful in its business initiatives and there is the possibility that the
Company will not be in business at some point in the future.

 

(l)       Survival.
The foregoing representations and warranties shall survive the Closing Date for a period of six months.

 

 

(m).       Additional
Risks.

 

1)
Federal regulation and enforcement may adversely affect the implementation of cannabis laws and regulations may negatively impact
our business operations, revenues and profits.

 

Currently,
there are 33 states in the United States, plus the District of Columbia, that have laws and/or regulations that recognize, in one
form or another, medical benefits or other uses for CBD infused or cannabis related products. These states have also passed laws
governing the use and sale of cannabis products and others are considering similar legislation. Our Tauri-GumTM product
line does not contain psychoactive substances also present in the cannabis plant, such as Tetrahydrocannabinol or THC.

 

    	-7-

    	 

    

 

Nonetheless,
at least some provisions of these state laws are in direct conflict with the United States Federal Controlled Substances Act (21 U.S.C.
§ 811) (“CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule
I drug, which is viewed as having a high potential for abuse, has no currently-accepted use for medical treatment in the U.S., and lacks
acceptable safety for use under medical supervision. Under the CSA, the policies and regulations of the federal government and its agencies
are that cannabis has no medical benefit and a range of activities including cultivation and the personal use of cannabis is prohibited.
Uncertainty remains the rule under the CSA. There is disagreement between the government and the courts regarding the precise scope of
the CSA. Some courts have held that CBD is excluded from the CSA, which they believe, only covers the THC chemical. Others have held
that CBD is covered by the CSA when it is derived from the cannabis plant. On December 20, 2018, the Agricultural Improvement Act of
2018 (the “2018 Farm Bill”) legalized the cultivation and production of hemp, a variation on the cannabis plant that contains
CBD but less than 0.3% THC (the psychoactive chemical of the cannabis plant), providing at least some certainty about sources of legal
CBD.

 

2
) New York City has implemented an embargo on food and beverage CBD products.

 

On
October 27, 2020 the State of New York has determined that it is allowable to sell CBD Infused Edible products in the forms of both food
and drink (inclusive of chewing gum). At no time can CBD be sold in products that contain either alcohol or tobacco.

 

Additionally:

 

●NO
CBD Product Can be Sold if it Contains More than 0.3% (1/333rd by Composition) THC

●No
                                            Individual Food or Beverage Product Can Contain More than 25mg of Hemp- Extracted Cannabinoids
                                            (“CBD” or “CBG”) per serving

●Food
                                            and Drink Infused with CBD and Other Hemp Extracts Must be Packaged by the Manufacturer

●Extracts
                                            can NOT be Added at the Retail Level

 

Tauriga
Sciences, Inc. is pleased to confirm that its flagship product line, branded as Tauri- GumTM, is fully compliant with all of the
updated New York State rules and regulations that have been established this week. The Company believes that these new standards that
have been set by New York will be helpful in driving greater market acceptance of ethical, high quality products such as Tauri-GumTM.

 

4.       Regulation
D Offering. The offer and issuance of the Securities to the Subscriber is being made pursuant to the exemption from the registration
provisions of the 1933 Act afforded by Section 4(2) or Section 4(6) of the 1933 Act and/or Rule 506 of Regulation D promulgated thereunder.

 

    	-8-

    	 

    

 

5.       Covenants
of the Company and Subscriber Regarding Indemnification.

 

(a)       The
Company agrees to indemnify, hold harmless, reimburse and defend the Subscriber, the Subscriber’ officers, directors, agents, affiliates,
control persons, and principal shareholders, against any claim, cost, expense, liability, obligation, loss or damage (including reasonable
legal fees) of any nature, incurred by or imposed upon the Subscriber or any such person which results, arises out of or is based upon
(i) any material misrepresentation by Company or breach of any warranty by Company in this Agreement or in any Exhibits or Schedules
attached hereto, or other agreement delivered pursuant hereto; or

 

(ii)       after
any applicable notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed
by the Company hereunder, or any other agreement entered into by the Company and Subscriber relating hereto.

 

(b)       The
Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors,
agents, affiliates, control persons against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal
fees) of any nature, incurred by or imposed upon the Company or any such person which results, arises out of or is based upon (i) any
material misrepresentation by such Subscriber in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered
pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by such Subscriber of
any covenant or undertaking to be performed by such Subscriber hereunder, or any other agreement entered into by the Company and Subscribers
relating hereto. (c)In no event shall the liability of any Subscriber or permitted successor hereunder or under any other agreement delivered
in connection herewith be greater in amount than the dollar amount of the net proceeds received by such Subscriber upon the sale of Registrable
Securities (as defined herein) giving rise to such indemnification obligation.

 

6.       Miscellaneous.

 

(a)       Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt
requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery,
telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written
notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated
below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following
such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on
the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual
receipt of such mailing, whichever shall first occur. The addresses for such communications shall be: (i) if to the Company, to: Tauriga
Sciences, Inc., 555 Madison Ave, 5th Floor / New York, NY 10022, and (ii) if to the Subscriber, to the address and telecopier
number indicated on the signature page hereto.

 

    	-9-

    	 

    

 

(b)       Closing.
The consummation of the transactions contemplated herein (“Closing”) shall take place at the offices of the Company
or via email upon the satisfaction of all conditions to Closing set forth in this Agreement.

 

(c)       Entire
Agreement; Assignment. This Agreement and other documents delivered in connection herewith represent the entire agreement between
the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties. Neither the
Company nor the Subscriber have relied on any representations not contained or referred to in this Agreement and the documents delivered
herewith. No right or obligation of either party shall be assigned by that party without prior notice to and the written consent of the
other party.

 

(d)       Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all
of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same
with the same force and effect as if such facsimile signature were the original thereof.

 

(e)       Law
Governing this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the State of New York
without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state of New York. The
parties and the individuals executing this Agreement and other agreements referred to herein or delivered in connection herewith on behalf
of the Company agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to
recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any
other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule
of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of
any other provision of any agreement.

 

(f)       Specific
Enforcement, Consent to Jurisdiction. The Company and Subscriber acknowledge and agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions
of this Agreement and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy
to which any of them may be entitled by law or equity. Each of the Company and Subscriber hereby waives, and agrees not to assert in
any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action
or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Nothing in this Section
shall affect or limit any right to serve process in any other manner permitted by law.

  

[SIGNATURE
PAGE FOLLOWS]

 

    	-10-

    	 

    

 

SIGNATURE PAGE TO SECURITIES
PURCHASE AGREEMENT

 

Please
acknowledge your acceptance of the foregoing Securities Purchase Agreement by signing and returning a copy to the undersigned whereupon
it shall become a binding agreement between us.

 

TAURIGA
SCIENCES, INC.

a
Florida Corporation

 

	 	By:	 	 
	 	Name:	Seth M. Shaw	 
	 	Title:	CEO/Chairman	 

 

    	-11-

    	 

    

 

	SUBSCRIBER	 
	 	 	 
	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 
	If
    Subscriber is an entity:	 

 

	Form
    of Entity:	Accredited
    Individual Investor	 
	 	 	(i.e.,
    corporation, partnership, etc.)
		 	 
	 	 	 
	Laws
    under which Entity is formed: N/A	 
	 	 	 
	Principal
    jurisdiction in which business is conducted: N/A	 
	 	 	 
		 	 
	Social
    Security or	 	 
	Tax
    Identification Number:                    	 
	 	 	 
	Signature	 
	(If
    signing as officer or partner, please give title)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]